Dietary Patterns and Nonmotor Symptoms in Parkinson’s Disease: A Cross-Sectional Analysis

Lawrie, Sophie; Coe, Shelly; Mansoubi, Maedeh; Welch, Jessica; Razzaque, Jamil; Hu, Michele T.M.; Dawes, Helen

doi:10.1080/07315724.2022.2056544

Cited by 6 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher MIND diet score was substantially associated with slower cognitive decline with aging in the MAP Study [ 17 ], and improved verbal memory scores in a population-based study of American women [ 43 ]. However, results still vary in this population, potentially due to differences in assessment tools and statistical power [ 30 ]. In this study, the non-motor PRO-PD sub-scale used assessed “memory/forgetfulness” and “comprehension” as cognitive measures, which were both found to be significantly improved from the MEDI diet and, more so, the MIND diet.…”

Section: Discussionmentioning

confidence: 99%

“…The PRO-PD has previously been shown to correlate with the number of years elapsed since PD diagnosis, quality of life and legacy measures of PD, such as Hoehn and Yahr (H-Y), Unified PD Rating Scale (UPDRS), Parkinson’s Disease Questionnaire-39 (PDQ-39), and Timed-Up-&-Go (TUG). However, the non-motor subset of the PRO-PD (PRO-PD(nm)) was highly correlated with the non-motor symptom scale (NMSS) [ 30 ].…”

Section: Methodsmentioning

confidence: 99%

“…There has been a limited number of studies investigating the impact of the MIND diet specifically in PD-associated NMS [ 25 , 26 , 30 ]. To our knowledge, no studies have compared the effects of MEDI and MIND diet adherence on motor and non-motor symptom severity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Associations between MIND and Mediterranean Diet Scores with Patient-Reported Outcomes in Parkinson’s Disease

Fox¹,

Park

Mischley

2022

Nutrients

View full text Add to dashboard Cite

The Mediterranean (MEDI) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets have been associated with a reduced risk of Parkinson’s disease (PD) diagnosis. However, studies evaluating whether these diets are associated with disease progression in those patients already diagnosed are lacking. The objective of this study was to evaluate whether MIND and MEDI scores were associated with improved patient-reported outcomes. Additionally, we sought to explore which questions on the MIND and MEDI scales were more strongly correlated with PD symptom severity. Data were obtained from the ongoing Modifiable Variables in Parkinsonism study, using patient-reported outcomes in Parkinson’s disease (PRO-PD) as the primary measure for symptom severity, and MIND and MEDI scales for diet score. After adjusting for age, gender, income, and years since diagnosis, for each 1-point increase in the MIND and MEDI scores, PRO-PD scores were 52.9 points lower (95%CI: −66.4, −39.4; p < 0.001) and 25.6 points lower (95%CI: −37.2, −14.0; p < 0.001), respectively (N = 1205). This study suggests MIND and MEDI scores are associated with fewer patient-reported symptoms over time, with each MIND point being twice as strong as a MEDI point in reducing symptom severity. Future dietary intervention trials should consider the MIND diet as a therapeutic strategy for improving long-term PD outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Associations between MIND and Mediterranean Diet Scores with Patient-Reported Outcomes in Parkinson’s Disease

Fox¹,

Park

Mischley

2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Although multifactorial interactions are involved in the prevalence and incidence of neurodegenerative diseases, nutrition plays an essential role in the pathogenesis and development of neurodegenerative diseases such as AD and PD [ 381 , 382 ]. Recent findings have revealed that diet, as a non-pharmacological element, plays an important role not only as a risk factor but also as a potential therapeutic approach for treating PD ( Table 3 ) [ 309 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 ]. The effects of diet intervention on PD development can be attributed to different mechanisms.…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

“…Interestingly, the findings of a cross-sectional study revealed that MIND diet adherence is associated with an older age of PD onset in a superior manner to that of the MD itself [ 383 ]. Furthermore, this diet may improve fatigue and depression in PD patients [ 393 ].…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Varesi¹,

Campagnoli²,

Fahmideh³

et al. 2022

IJMS

View full text Add to dashboard Cite

The bidirectional interaction between the gut microbiota (GM) and the Central Nervous System, the so-called gut microbiota brain axis (GMBA), deeply affects brain function and has an important impact on the development of neurodegenerative diseases. In Parkinson’s disease (PD), gastrointestinal symptoms often precede the onset of motor and non-motor manifestations, and alterations in the GM composition accompany disease pathogenesis. Several studies have been conducted to unravel the role of dysbiosis and intestinal permeability in PD onset and progression, but the therapeutic and diagnostic applications of GM modifying approaches remain to be fully elucidated. After a brief introduction on the involvement of GMBA in the disease, we present evidence for GM alterations and leaky gut in PD patients. According to these data, we then review the potential of GM-based signatures to serve as disease biomarkers and we highlight the emerging role of probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation as supportive therapeutic approaches in PD. Finally, we analyze the mutual influence between commonly prescribed PD medications and gut-microbiota, and we offer insights on the involvement also of nasal and oral microbiota in PD pathology, thus providing a comprehensive and up-to-date overview on the role of microbial features in disease diagnosis and treatment.

show abstract

Improvement of fatigue in generalised myasthenia gravis with zilucoplan

Weiss,

Freimer,

Leite

et al. 2024

J Neurol

View full text Add to dashboard Cite

Background Fatigue is a debilitating symptom of myasthenia gravis (MG). The impact of fatigue on MG can be assessed by Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Fatigue scale. Transformation of raw Neuro-QoL fatigue scores to T-scores is a known approach for facilitating clinical interpretation of clinically meaningful and fatigue severity thresholds. Methods In the Phase 3, double-blind, placebo-controlled RAISE study (NCT04115293), adults with acetylcholine receptor autoantibody-positive generalised MG (MG Foundation of America Disease Class II–IV) were randomised 1:1 to daily subcutaneous zilucoplan 0.3 mg/kg or placebo for 12 weeks. Patients completing RAISE could opt to receive zilucoplan 0.3 mg/kg in an ongoing, open-label extension study, RAISE-XT (NCT04225871). In this post-hoc analysis, we evaluated the long-term effect of zilucoplan on fatigue in RAISE patients who entered RAISE-XT. We report change in Neuro-QoL Short Form Fatigue T-scores and fatigue severity levels from RAISE baseline to Week 60. Results Mean Neuro-QoL Short Form Fatigue T-scores improved from baseline to Week 12 in the zilucoplan group (n = 86) with a clinically meaningful difference versus placebo (n = 88; least squares mean difference: − 3.61 (nominal p-value = 0.0060]), and these improvements continued further to Week 60. At Week 12, more patients on zilucoplan (n = 34, 47.2%) experienced improvements in ≥ 1 fatigue severity level from baseline versus placebo (n = 23, 28.4%; p = 0.017). At Week 60, most (n = 55, 65.5%) patients had mild fatigue or none. Conclusion Treatment with zilucoplan demonstrated statistical and clinically meaningful improvements in fatigue scores and severity versus placebo during RAISE, which were sustained to Week 60 in RAISE-XT.

show abstract

Dietary Patterns and Nonmotor Symptoms in Parkinson’s Disease: A Cross-Sectional Analysis

Cited by 6 publications

References 57 publications

Comparison of Associations between MIND and Mediterranean Diet Scores with Patient-Reported Outcomes in Parkinson’s Disease

Comparison of Associations between MIND and Mediterranean Diet Scores with Patient-Reported Outcomes in Parkinson’s Disease

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Improvement of fatigue in generalised myasthenia gravis with zilucoplan

Contact Info

Product

Resources

About